The Behavioral and Neural Effects of Oxytocin on Face Perception in Congenital Prosopagnosia
Trial Snapshot
- Phase
- Early Phase 1
- Status
- Suspended
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Memory performance
Study Overview
Brief Summary
The purpose of this study is to determine whether oxytocin affect face perception
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Basic Science
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •normal or corrected to normal vision
Exclusion Criteria
- •pregnancy (according to a pregnancy test taken by subjects prior to participation)
- •a history of asthma or nasal polyps
- •cardiac disorders
- •hyponatremia
- •acute or chronic renal insufficiency
- •liver cirrhosis
- •neurological disease
- •other chronic disease
- •dementia, or lack of judgment
Arms & Interventions
Control group
Control group will be administered oxytocin and placebo, in a double-blind randomized order.
Intervention: Oxytocin (Drug)
Control group
Control group will be administered oxytocin and placebo, in a double-blind randomized order.
Intervention: Placebo (Drug)
congenital prosopagnosia
Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
Intervention: Oxytocin (Drug)
congenital prosopagnosia
Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Memory performance
Time Frame: Day 2 (24 hours after encoding)
At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are %accuracy and %dwell time of eye movements towards each region in the faces the participants saw.
Secondary Outcomes
- Mood measurement(Day 1 (after oxytocin/placebo uptake))
Investigators
Ilan Shelef
Head of medical imaging at Soroka University Medical Center
Soroka University Medical Center